FSSAI files three cases against Nestlé India over infant nutrition products
FSSAI has initiated three adjudication proceedings involving alleged prohibited promotional claims for NAN Excella Pro Stage 1 and Lactogen Pro 1, plus sub-standard biotin content in a follow-up formula. Nestlé India shares fell 2.57% intraday.
What happened
FSSAI initiated three adjudication cases against Nestle India over alleged prohibited promotional claims for NAN Excella Pro Stage 1 and Lactogen Pro 1, and
Key facts
- Shares fell 2.57% to an intraday low of Rs 1,332.80 on NSE
- One-year gain narrowed to 7.37%
- Three separate adjudication cases filed
- Regulation 4(2) of the Food Safety and Standards (Foods for Infant Nutrition) Regulations, 2020
- Section 3 of the Infant Milk Substitutes Act, 1992
Why this matters
Any infant-nutrition partnership or acquisition should receive enhanced diligence on FSSAI compliance, marketing claims and product-quality controls.
What to watch
- FSSAI adjudication notices, hearing dates, orders, penalties or product-specific corrective directives
- Any recall, stop-sale, relabeling, reformulation or import/supply disruption involving NAN Excella Pro Stage 1, Lactogen Pro 1 or the cited follow-up formula
- Nestlé India disclosures on provisions, legal contingencies, sales impact or increased quality/compliance expenditure
- Expansion of testing or enforcement to additional Nestlé products, manufacturing sites or infant-nutrition companies
- Retailer, e-commerce, hospital or healthcare-professional restrictions on product visibility or promotion
- Consumer complaints, social-media traction and mainstream coverage linking the cases to infant safety or breastfeeding-code compliance
- Nestlé India will likely issue a regulatory-compliance response, emphasizing product safety, legal process and corrective cooperation.
- The company may review or suspend disputed promotional materials across medical, digital, retail and distributor channels.
- FSSAI may seek product samples, substantiation records, labeling details and corrective-action timelines.
- Retailers and e-commerce platforms may increase diligence on infant-nutrition listings and claims even without a formal product withdrawal.
- Competitors may avoid comparative marketing and strengthen claim substantiation, while seeking share gains through trust-focused messaging.